Compare · IMAC vs LH
IMAC vs LH
Side-by-side comparison of IMAC Holdings Inc. (IMAC) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMAC and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
- LH is the larger of the two at $21.68B, about 636.4x IMAC ($34.1M).
- LH has hit the wire 7 times in the past 4 weeks while IMAC has been quiet.
- LH has more recent analyst coverage (25 ratings vs 1 for IMAC).
- Company
- IMAC Holdings Inc.
- Labcorp Holdings Inc.
- Price
- $1.01+9.76%
- $263.82-0.44%
- Market cap
- $34.1M
- $21.68B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 0
- 7
- Recent ratings
- 1
- 25
IMAC Holdings Inc.
IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. Its outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. The company operates 16 outpatient clinics in Kentucky, Missouri, Tennessee, Illinois, and Florida. IMAC Holdings, Inc. was founded in 2000 and is based in Brentwood, Tennessee.
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest IMAC
- SEC Form SC 13G filed by IMAC Holdings Inc.
- SEC Form 10-Q filed by IMAC Holdings Inc.
- SEC Form 4: Sucoff Cary was granted 100,000 shares, increasing direct ownership by 100% to 200,000 units
- SEC Form 4: Evans Maurice E. was granted 100,000 shares, increasing direct ownership by 89% to 212,420 units
- SEC Form 4: Pruitt Michael D was granted 100,000 shares and covered exercise/tax liability with 37,000 shares, increasing direct ownership by 62% to 164,250 units
- SEC Form EFFECT filed by IMAC Holdings Inc.
- SEC Form S-3/A filed by IMAC Holdings Inc. (Amendment)
- SEC Form S-3 filed by IMAC Holdings Inc.
- IMAC Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form SC 13G/A filed by IMAC Holdings Inc. (Amendment)
Latest LH
- Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®
- Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes
- Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research
- SEC Form DEFA14A filed by Labcorp Holdings Inc.
- SEC Form DEF 14A filed by Labcorp Holdings Inc.
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp Declares Quarterly Dividend
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp to Announce First Quarter Financial Results on April 30, 2026
- SEC Form 4 filed by Schechter Adam H